Careers Contact

Evaxion > Investors

Investors

Since 2021, Evaxion has been listed on the Nasdaq Capital Market exchange (ticker code: EVAX). Here you can find all of the latest Evaxion investor insights: our results, upcoming events and news, important shareholder updates and much more.

Latest press releases

Evaxion announce 2026 financial calendar

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Evaxion announces business update and third quarter 2025 financial results

Upcoming events & presentations

Nov 13 – Nov 14, 2025

NextGen Omics & Data 2025

Bringing together 1000+ key scientific researchers, pharma representatives, & healthcare leaders under one roof to accelerate omics research across therapeutic areas through our NGS & Clinical Diagnostics; Multi-Omics in Single Cell and Spatial Analysis; NextGen Omics Data & Analysis; & Liquid Biopsies programmes. Click here to learn more about the conference.

Latest events & presentations

Nov 13 – Nov 14, 2025

London, United Kingdom

NextGen Omics & Data 2025

Bringing together 1000+ key scientific researchers, pharma representatives, & healthcare leaders under one roof to accelerate omics research across therapeutic areas through our NGS & Clinical Diagnostics; Multi-Omics in Single Cell and Spatial Analysis; NextGen Omics Data & Analysis; & Liquid Biopsies programmes.

Q3

Latest quarterly report

View all financial reports

Presentation

Webcast

Transcript

Press release

Contact IR

Mads Kronborg
Vice President, Investor Relations & Communication
Email: mak@evaxion.ai
Telephone: +45 53 54 82 96

For general investor relations inquiries please use the contact form below

Company presentation

Stay in touch

LinkedIn

Follow Evaxion on LinkedIn to engage, connect, and stay informed.

Twitter

Join the conversation and stay updated with Evaxion on X.

Subscribe to email news alerts

Join our mailing list to get our latest press releases delivered straight to your inbox.